Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
JACC - Journal of the American College of Cardiology,

Hsia J et al. - Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein 2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events.

Methods
  • A cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein 2 mg/l and LDL-C <130 mg/dl were randomly allocated to rosuvastatin 20 mg daily or placebo, and followed up for all-cause mortality, major cardiovascular events, and adverse events.
  • In a post-hoc analysis, participants allocated to rosuvastatin were categorized as to whether or not they had a follow-up LDL-C level <50 mg/dl.

Results
  • A median follow-up of 2 years (range up to 5 years) was conducted
  • Rates of the primary trial endpoint were 1.18, 0.86, and 0.44 per 100 person-years in the placebo group (n = 8,150) and rosuvastatin groups without LDL-C <50 mg/dl (n = 4,000) or with LDL-C <50 mg/dl (n = 4,154), respectively (fully-adjusted hazard ratio: 0.76; 95% confidence interval: 0.57 to 1.00 for subjects with no LDL-C <50 mg/dl vs. placebo and 0.35, 95% confidence interval: 0.25 to 0.49 for subjects attaining LDL-C <50 mg/dl; p for trend <0.0001)
  • For all-cause mortality, corresponding event rates were 0.67, 0.65, and 0.39 (p for trend = 0.004)
  • Rates of myalgia, muscle weakness, neuropsychiatric conditions, cancer, and diabetes mellitus were not significantly different among rosuvastatin-allocated participants with and without LDL-C <50 mg/dl

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

1 Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation European Heart Journal, September 16, 2014    Clinical Article

2 Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials Hypertension, September 29, 2014    Evidence Based Medicine    Review Article

3 Effects of tea intake on blood pressure: A meta-analysis of 21 randomized controlled trials JACC - Journal of the American College of Cardiology, October 22, 2014    Clinical Article

4 A systematic review of statin-induced muscle problems in clinical trials American Heart Journal, October 7, 2014    Review Article

5 Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy EP Europace, September 19, 2014    Clinical Article

6 Effect of statins in preventing contrast-induced nephropathy: an updated meta-analysis Coronary Artery Disease, October 2, 2014    Clinical Article

7 Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease The American Journal of Cardiology, September 5, 2014    Clinical Article

8 Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population American Heart Journal, October 6, 2014    Clinical Article

9 Effect of Nicorandil in patients with heart failure: A systematic review and meta-analysis Cardiovascular Therapeutics, October 17, 2014    Evidence Based Medicine    Review Article    Clinical Article

10 New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities Drugs, October 10, 2014    Review Article

11 The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: Results of a randomized trial American Heart Journal, October 1, 2014    Clinical Article

12 Effect of different dose aspirin on coronary artery lesions in the acute phase of Kawasaki disease JACC - Journal of the American College of Cardiology, October 21, 2014    Clinical Article

13 Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid Journal of Thrombosis and Haemostasis, September 25, 2014    Clinical Article

14 Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion Clinical Therapeutics, August 19, 2014    Clinical Article

15 Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: A subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial American Heart Journal, October 13, 2014    Clinical Article

16 Tea consumption is inversely related to 5-year blood pressure change among adults in Jiangsu, China: A cross-sectional study Full Text Nutrition Journal, October 24, 2014    Free full text    Clinical Article

17 Endovascular versus medical therapy for atherosclerotic renovascular disease Current Atherosclerosis Reports, October 23, 2014    Clinical Article

18 Starting primary prevention earlier with statins The American Journal of Cardiology, October 15, 2014    Clinical Article

19 Ischemic postconditioning versus remote ischemic conditioning in patients treated with primary percutaneous coronary intervention: A Bayesian network meta-analysis JACC - Journal of the American College of Cardiology, October 16, 2014    Clinical Article

20 Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel Journal of Clinical Pharmacy and Therapeutics, September 24, 2014    Clinical Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore